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and Lawrence, 2000). Moreover, there are so many exam-RhoGAP: The Next Big
ples in which growth and proliferation are physiologicallyThing for Small Mice? uncoupled that one is forced to at least consider the
possibility that these two processes might generally be
regulated independently. For example, reductive cleav-
ages in most early embryos represent cell division with-
out growth, whereas the opposite occurs in a hypertro-
The size of an organism is determined by the number phic muscle cell or a megakaryocyte, the giant bone
and size of its constituent cells. The insulin/IGF-1 sig- marrow cell that sheds platelets. Interestingly, the latter
naling systems have been long recognized to play a cell represents an example of the rule that DNA content
critical role in the determination of body size. Now the directly correlates with cell size, as it is the repeated
generation of mice deficient for a RhoGAP suggests rounds of DNA synthesis unaccompanied by cell divi-
that this small G protein might also regulate the growth sion that accounts for the bulk of the megakaryocyte.
of animals. Another principle guiding the determination of organ
size is that alterations in proliferation are compensated
by inverse changes in cell size, such that the volumeIn a time marked by impressive advances in the elucida-
of the compartment remains unchanged. Thus, we aretion of both principles and details governing develop-
presented with an intriguing paradox: while the majorment, one of the most poorly understood processes
factor responsible for differences in size among organ-is the determination of the mature size of organs and
isms is the number rather the size of the constituentorganisms. While we all accept the consistency by which
cells, the primary determinant of organ size within anhuman arms are bilaterally roughly equal in size and
organism is the rate of growth and not proliferation.smaller than legs and that humans are invariably larger
Over the past several years, a number of lines of inves-than mice, the molecular mechanisms that ensure the
tigation have converged on the evolutionarily conservedfidelity of these phenomena are only beginning to be
insulin/IGF-1 signaling pathway as a critical regulator ofunderstood. Thus, the report by Sordella et al. in this
cell growth (Day and Lawrence, 2000). Some of the mostissue of Developmental Cell, pointing to a surprising
informative data derive from genetic experiments in thepathway that regulates cell size, represents a potentially
fruit fly, Drosophila melanogaster, though confirmatoryimportant contribution to the solution of this problem
information has begun to emerge in mammals. The criti-(Sordella et al., 2002).
cal signaling components include, in addition to theThree fundamental processes principally regulate bio-
insulin receptor and its substrate chico (the fruit flylogical mass: cell proliferation, death, and growth (used
homolog of mammalian insulin receptor substrate 1),here to indicate the determination of cell size irrespec-
phosphoinositide 3-kinase, phosphoinositide-depen-tive of rates of division). Whereas the first two have
dent protein kinase 1, Akt/protein kinase B, and S6 pro-received substantial attention in recent decades, only
tein kinase and PHAS1/4EBP1, though the latter twoin the last several years have scientists begun to address
translational regulators might well be more responsivethe problem of regulation of cell growth. Perhaps the
to nutritional cues than insulin. Suggesting a surprisinglyrelatively constant size of most cells has caused many
linear cascade, overexpression of each member of thisof us to forget that proliferation must be accompanied
pathway yields a virtually equivalent phenotype, an in-by a commensurate, perfectly matched increase in
crease in compartment size mediated by a dispropor-growth, or over time cell size will drift. The simplistic
tionate augmentation in cell growth. The lipid phospha-but rather tempting view that growth always follows
tase PTEN functions as a negative regulator of thepassively as a direct result of proliferation has never fit
pathway.the data particularly well, but only recently has it been
refuted using modern cellular and genetic strategies (Day In the present report, Sordella et al. have generated
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Rho Inhibits Insulin Signaling
This figure shows a portion of the signaling
cascade modulated by insulin and a model
by which Rho might suppress this pathway.
When insulin binds to its receptor, it activates
the latter’s intrinsic tyrosine kinase activity.
The receptor then phosphorylates IRS1,
which serves as a docking site for a number
of signaling proteins, including PI 3-kinase.
Generation of 3 phosphoinositides leads to
activation of Akt/PKB, which phosphorylates
CREB, stimulates glucose oxidation, protein
synthesis, and, ultimately, cell growth. Loss
of p190-B RhoGAP results in elevated Rho
activity, leading to stimulation of Rho kinase (ROK). This phosphorylates IRS1 on serine residues, which inhibit subsequent tyrosine phosphoryla-
tion, the net effect a dampening of this pathway and a reduction in cell growth.
mice deficient for one of the two known 190 kDa Rho src homology 2 (SH2) domains present in the latter.
Interestingly, phosphorylation of IRS on serine and thre-GTPase-activating proteins, p190-B RhoGAP (Sordella
et al., 2002). Rho is itself a small GTPase capable of onine residues tends to inhibit subsequent tyrosine
phosphorylation, and thus downregulate the system.influencing a number of important biological processes,
most notably organization of the actin cytoskeleton but The recent indication that Rho kinase (ROK) can function
as an IRS serine/threonine suggests a mechanism link-also vesicular trafficking and transformation. Like all G
proteins, Rho is active when associated with GTP, but ing hyperactivity of Rho to decreased insulin/IGF-1 sig-
naling (Farah et al., 1998) (see Figure). Using fibroblastsconstantly recycles between this state and the inactive,
GDP-bound form. Thus, since p190-B RhoGAP cata- derived from p190-B RhoGAP null mice, Sordella et al.
show this to be the case, and, moreover, demonstratelyzes the conversion of Rho-GTP to Rho-GDP, it is not
unanticipated that cells derived from the null animals that insulin signaling can be rescued by a ROK inhibitor
(see Figure). Most of the interest in inhibitory IRS serine/demonstrate constitutive activation of Rho. Much more
surprising, however, are two conspicuous aspects of threonine phosphorylation has been driven by the idea
that this process is an etiological factor in the insulinthe phenotype of the p190-B RhoGAP mice. First, these
animals bear a striking resemblance to mice deficient resistance of type 2 diabetes mellitus (Birnbaum, 2001);
thus, though the p190-B RhoGAP knockout die beforein the transcription factor CREB, which binds to the
canonical cyclic AMP response element (Rudolph et al., they have the opportunity to develop diabetes, it will
be interesting to see whether increased Rho activity is1998). More direct evidence of the link between the two
knockout models is provided by the decreased phos- associated with insulin resistance in other mouse mod-
els or human diabetes.phorylation at a crucial regulatory serine residue in
CREB evident in most tissues form the p190-B RhoGAP The data of Sordella et al. present some intriguing
questions that should be answerable in the near future.null mice. Second, the latter mice are about 30% smaller
than their wild-type littermates at birth and die soon First, the connection between early insulin signaling and
CREB phosphorylation remains unclear. Though Sor-thereafter. These data immediately suggest a model in
which an important determinant of organismal size is della et al. show the phosphorylation of several insulin-
dependent kinases to be reduced in tissues from theCREB phosphorylation, and that Rho regulates this pro-
cess. Even more unexpected is the mechanism by which p190-B RhoGAP null mice, Akt/PKB must be regarded
as the prime suspect, given its well-established role inbody size is reduced; in virtually all organs examined,
there was a decrease in cell size, as demonstrated most the regulation of cell growth in both Drosophila and
mammals (Tuttle et al., 2001; Verdu et al., 1999). In fact,convincingly by a reduction in the ratio of protein to
DNA (Sordella et al., 2002). One oddity of the phenotype mice deficient in Akt1/PKBare small at birth and remain
so throughout life (Cho et al., 2001). Moreover, Akt/PKBis that, with the exception of the thymus, most organs
are proportionally reduced in size, even though a number has been shown to phosphorylate CREB directly (Du and
Montminy, 1998). Much more perplexing is how CREBof tissues extracts do not reveal reduction in phospho-
CREB immunoreactivity. These data might be hinting at is affecting cell growth. For example, in the mammalian
liver, insulin and cyclic AMP are antagonistic in the regu-a presently obscure noncell-autonomous component to
regulation of cell growth by p190-B RhoGAP. lation of glucose production, so it is difficult to imagine
how the same signaling paths could cooperate for cellWhat then is the mechanism by which activation of
Rho secondary to a loss of p190-B RhoGAP leads to growth. Last, much more information is needed as to
whether reduction in insulin/IGF-1 signaling alone is suf-phosphorylation of CREB? Here again, Sordella et al.
provide a plausible and tantalizing model. Unlike most ficient to disproportionately reduce cell growth in mam-
mals. Though IGF-1 receptor knockout mouse are small,protein tyrosine kinase receptors, insulin and IGF-1 do
not assemble signaling complexes on the receptor itself, it has been difficult to demonstrate any significant re-
duction in the size of individual cells, but instead a de-but rely on a family of scaffolding proteins, the insulin
receptor substrates (IRS1-4). The hormone-bound re- crease in cell number has been blamed for the altered
body size (Liu et al., 1993). Whether alternative mecha-ceptor phosphorylates IRS on a number of tyrosine resi-
dues, which serve to dock key signaling molecules via nisms compensate for loss of IGF-1 signaling in this
Previews
523
Day, S.J., and Lawrence, P.A. (2000). Development 127, 2977–2987.model, or Rho acts on targets in addition to IRS to
Du, K., and Montminy, M. (1998). J. Biol. Chem. 273, 32377–32379.suppress growth, the discovery of a role for p190-B
RhoGAP in cell size regulation is certain to provoke a Farah, S., Agazie, Y., Ohan, N., Ngsee, J.K., and Liu, X.J. (1998). J.
Biol. Chem. 273, 4740–4746.wealth of new and informative experimentation.
Liu, J.P., Baker, J., Perkins, A.S., Robertson, E.J., and Efstratiadis,
A. (1993). Cell 75, 59–72.Morris J. Birnbaum
Rudolph, D., Tafuri, A., Gass, P., Hammerling, G.J., Arnold, B., andHoward Hughes Medical Institute
Schutz, G. (1998). Proc. Natl. Acad. Sci. USA 95, 4481–4486.University of Pennsylvania School of Medicine
Sordella, R., Classon, M., Hu, K.-Q., Matheson, S.F., Brouns, M.R.,415 Curie Boulevard
Fine, B., Zhang, L., Takami, H., Yamada, Y., and Settleman, J. (2002).Philadelphia, Pennsylvania 19104
Dev. Cell 2, this issue, 553–565.
Tuttle, R.L., Gill, N.S., Pugh, W., Lee, J.P., Koeberlein, B., Furth,Selected Reading
E.E., Polonsky, K.S., Naji, A., and Birnbaum, M.J. (2001). Nat. Med.
7, 1133–1137.Birnbaum, M.J. (2001). J. Clin. Invest. 108, 655–659.
Verdu, J., Buratovich, M.A., Wilder, E.L., and Birnbaum, M.J. (1999).Cho, H., Thorvaldsen, J.L., Chu, Q., Feng, F., and Birnbaum, M.J.
(2001). J. Biol. Chem. 276, 38349–38352. Nat. Cell Biol. 1, 500–506.
